NCT05326516 - A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

July 29, 2024

Study Completion Date

July 29, 2024

Conditions

Relapsed/Refractory LeukemiasAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaMixed Phenotype Acute LeukemiaAcute Myeloid LeukemiaAcute Undifferentiated Leukemia

Interventions

DRUG

Revumenib

Participants will receive revumenib until meeting criteria for discontinuation.

DRUG

Chemotherapy Regimen 1

Participants will receive 2 treatment cycles of chemotherapy. During Cycle 1, participants will receive prednisone, vincristine, pegaspargase/calaspargase pegol-mknL, and daunorubicin. During Cycle 2, participants will receive etoposide and cyclophosphamide.

DRUG

Chemotherapy Regimen 2

Participants will receive 2 treatment cycles of chemotherapy. During Cycles 1 and 2, participants will receive fludarabine and cytarabine.

Trial Locations (11)

10021

David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

19104

The Children's Hospital of Philadelphia, Philadelphia

38105

St. Jude Children's Research Hospital, Inc, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

63110

Washington University School of Medicine, St Louis

64108

Children's Mercy Hospital, Kansas City

77030

MD Anderson Cancer Center, Houston

Texas Children's Cancer and Hematology Center, Houston

94158

University of California, San Francisco (UCSF) Benioff Children's Hospital, San Francisco

02115

Dana-Farber Cancer Institute, Boston

QC H3T 1E2

Jewish General Hospital, Québec